NLS

Swedish Medtech Company Aerocrine was formed in 1997, based on research conducted at the Karolinska Institute investigating nitric oxide (NO) as an indicator for inflammatory processes, such as asthma. Aerocrine has developed devices to measure nitric oxide in exhaled air and these are used to both diagnose and follow the treatment of asthma. Aerocrine does […]

Karolinska Development has some interesting companies in its portfolio but has yet to show that it is capable of out-licensing projects to major pharmaceutical companies.

Orphan drugs are a classification of medicines for rare diseases. The market for those medicines is relatively small due to the low number of patients. Since development of pharmaceuticals is expensive, special incentives have been created to encourage pharma and biotech companies to conduct research. As a result a special orphan status was developed in […]

AstraZeneca has acquired the San Diego-based biotech firm Ardea Biosciences for 1.26 billion USD, approximately 8.4 billion SEK. The deal was presented in April, just months after AstraZeneca announced substantial restructuring in research and development at its operations in Södertälje, resulting in the lay-off of about 1200 researchers and personnel. “There is a lot of […]

The Swedish biotech company Swedish Orphan Biovitrum (Sobi) works within specialty pharma. The company was formed in 2001 as Biovitrum, a spinoff from Pharmacia, and registered on the stock market in 2006. In 2009 Biovitrum acquired the company Swedish Orphan for 3.9 billion Swedish crowns, a price many analysts considered too high. The new company […]

The Danish biotech firm Action Pharma impressed the market in early May by selling a drug candidate to pharmaceutical company Abbott for 110 million USD, approximately 780 million Swedish crowns. The drug candidate goes under the name of AP214 and is used to prevent acute kidney injury during cardiac surgery. The whole amount, 110 million […]